Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis

Cancer Research

Volumn 70, Issue 10, 2010, Pages 4141-4150

  Hawinkels, Lukas J A C ^a   Kuiper, Patricia ^a   Wiercinska, Eliza ^a   Verspaget, Hein W ^a   Liu, Zhen ^a   Pardali, Evangelia ^a   Sier, Cornelis F M ^a   Ten Dijke, Peter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; MATRIX METALLOPROTEINASE 14; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ADENOMA; ANIMALS; ANTIGENS, CD; CELL MEMBRANE; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COLON; COLORECTAL NEOPLASMS; COS CELLS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 14; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; RECTUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; UMBILICAL VEINS;

EID: 77952828002     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4466     Document Type: Article

References (47)

1. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: evidence and potential applications. FASEB J 2003;17: 984-992 (Pubitemid 36676386)
2. Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-β superfamily coreceptors in cancer. Biochim Biophys Acta 2009;1792:954-973
3. Li C, Guo B, Bernabeu C, Kumar S. Angiogenesis in breast cancer: the role of transforming growth factor-β and CD105. Microsc Res Tech 2001;52:437-449 (Pubitemid 32167832)
4. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003;22:6557-6563 (Pubitemid 37372335)
5. Arthur HM, Ure J, Smith AJ, et al. Endoglin, an ancillary TGF-β receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000;217:42-53. (Pubitemid 30046798)
6. Romani AA, Borghetti AF, Del Rio P, Sianesi M, Soliani P. The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count. J Surg Oncol 2006;93:446-455 (Pubitemid 44651267)
7. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-β pathways. J Biol Chem 2002;277:43799-43808 (Pubitemid 36157800)
8. Fonsatti E, Del Vecchio L, Altomonte M, et al. Endoglin: an accessory component of the TGF-β-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001;188:1-7. (Pubitemid 32476491)
9. Yinon Y, Nevo O, Xu J, et al. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-β3.AmJ Pathol 2008;172:77-85.
10. Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355: 992-1005. (Pubitemid 44343543)
11. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-649 (Pubitemid 43865232)
12. Li C, Guo B, Wilson PB, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 2000;89:122-126 (Pubitemid 30185919)
13. Li C, Gardy R, Seon BK, et al. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003;88:1424-1431 (Pubitemid 36606427)
14. Takahashi N, Kawanishi-Tabata R, Haba A, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001;7:524-532 (Pubitemid 32707974)
15. Liu C, Xu P, Lamouille S, Xu J, Derynck R. TACE-mediated ectodomain shedding of the type I TGF-β receptor downregulates TGF-β signaling. Mol Cell 2009;35:26-36.
16. Velasco-Loyden G, Arribas J, Lopez-Casillas F. The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J Biol Chem 2004;279: 7721-7733 (Pubitemid 38294655)
17. Walshe TE, Saint-Geniez M, Maharaj AS, Sekiyama E, Maldonado AE, D'Amore PA. TGF-β is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One 2009;4:e5149.
18. Ganesh S, Sier CF, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994;54:4065-4071 (Pubitemid 24258110)
19. Sier CF, Verspaget HW, Griffioen G, et al. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology 1991;101:1522-1528
20. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-β and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510-2516 (Pubitemid 43919684)
21. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-2756
22. Fontijn R, Hop C, Brinkman HJ, et al. Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16 E6/E7 DNA. Exp Cell Res 1995;216:199-207.
23. Hawinkels LJ, Verspaget HW, van Duijn W, et al. Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients. Br J Cancer 2007;97:398-404. (Pubitemid 47196749)
24. Hawinkels LJ, Zuidwijk K, Verspaget HW, et al. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer 2008;44:1904-1913
25. Hawinkels LJ, van Rossenberg SM, de Jonge-Muller ES, et al. Efficient degradation-aided selection of protease inhibitors by phage display. Biochem Biophys Res Commun 2007;364:549-555
26. Deckers M, van der Pluijm G, Dooijewaard S, et al. Effect of angiogenic and antiangiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants. Lab Invest 2001;81:5-15. (Pubitemid 32108635)
27. Sier CF, Hawinkels LJ, Zijlmans HJ, et al. Endothelium specific matrilysin (MMP-7) expression in human cancers. Matrix Biol 2008;27: 267-271
28. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-β receptors I and II. J Biol Chem 2002; 277:29197-29209
29. Zhou J, Olson BL, Windsor LJ. Nicotine increases the collagen-degrading ability of human gingival fibroblasts. J Periodontal Res 2007;42:228-235
30. Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008;19:52-60. (Pubitemid 350235981)
31. Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007;42:113-185 (Pubitemid 46911962)
32. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003;253:269-285
33. Chabottaux V, Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007; 24:647-656 (Pubitemid 350159738)
34. Sier CF, Zuidwijk K, Zijlmans HJ, et al. EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. Int J Cancer 2006;118:2991-2998
35. Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 2002;115:3427-3438 (Pubitemid 34994032)
36. Ding S, Li C, Lin S, et al. Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol 2006;37:861-866 (Pubitemid 43902946)
37. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001;7:3410-3415 (Pubitemid 33069974)
38. Sitras V, Paulssen RH, Gronaas H, et al. Differential placental gene expression in severe preeclampsia. Placenta 2009;30:424-433
39. Scharpfenecker M, van Dinther M, Liu Z, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007;120:964-972 (Pubitemid 46638511)
40. Calabro L, Fonsatti E, Bellomo G, et al. Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol 2003; 194:171-175 (Pubitemid 36043631)
41. Furstenberger G, von Moos R, Lucas R, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 2006;94: 524-531 (Pubitemid 43289756)
42. Mysliwiec P, Pawlak K, Kuklinski A, Kedra B. Combined perioperative plasma endoglin and VEGF-A assessment in colorectal cancer patients. Folia Histochem Cytobiol 2008;46:487-492
43. Bellone G, Solerio D, Chiusa L, et al. Transforming growth factor-β binding receptor endoglin (CD105) Expression in esophageal cancer and in adjacent nontumorous esophagus as prognostic predictor of recurrence. Ann Surg Oncol 2007;143:3232-3242 (Pubitemid 47594285)
44. Mysliwiec P, Pawlak K, Bandurski R, Kedra B. Soluble angiogenesis markers in gastric tumor patients. Folia Histochem Cytobiol 2009;47: 81-86
45. Liu Z, Kobayashi K, van Dinther M, et al. VEGF and inhibitors of TGF-β type-I receptor kinase synergistically promote blood-vessel formation by inducing α5-integrin expression. J Cell Sci 2009;122: 3294-3302
46. Cunha S, Pardali E, Thorikay M, et al. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 2010;207:85-100.
47. Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009;69:1517-1526